Log in
Enquire now
‌

Cytocybernetics Inc SBIR Phase I Award, July 2020

A SBIR Phase I contract was awarded to Cytocybernetics Inc in July, 2020 for $250,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1915151
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
‌
Cytocybernetics Inc
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R43HL150989-01A10
Award Phase
Phase I0
Award Amount (USD)
250,0000
Date Awarded
July 9, 2020
0
End Date
August 31, 2021
0
Abstract

Optical assays are a powerful tool in cellular electrophysiology. However, currently-available approaches have not reached their full potential. The major limitation of existing optical systems is that they are unable to determine the absolute voltage in the cell. Current commercial approaches report only qualitative relative changes in voltage, andamp; there is no information on absolute resting potential, diastolic potential, or action potential amplitude. Prior research attempts to develop absolute voltage reports have been unsuccessful. In addition, currently available voltage- sensitive dyes (VSDs) offer a very limited experimental duration (typically andlt; 30 min) dyes due to: 1) high washout andamp; internalization rates, which removes them from the electrically active cell membrane; 2) high photo-toxicity, which reduces the possible exposure time for measurements; andamp; 3) acute dye toxicity, which limits membrane loading andamp; illumination, resulting in small signals andamp; low signal to noise ratio.This proposal overcomes these 2 major obstacles to develop andamp; optimize our novel system which combines our VSDs andamp; our unique andamp; robust optical andamp; analytical system which determines absolute membrane potential. Our integrated quantitative Optical Electrophysiology (qOEP) system consists of our patented long lasting VSDs, optimized experimental protocols, optical detection system, andamp; analytical software. Our VSDs, which operate in the red/NIR spectral range, have reduced acute chemical andamp; photo-toxicity, increased sensitivity, andamp; slower washout/ internalization rate. This gives them the ability to be used in experiments up to 4 hours. This dramatic improvement revolutionizes the types of experiment which can be performed. Specifically, slower internalization rate gives the experimenter time to calibrate the VSD, so that the measured light intensity can be directly correlated with transmembrane potential. The spectral properties andamp; stability of this new generation of VSDs has been combined with advances in electronics andamp; circuitry that increase signal sensitivity andamp; allow for qOEP. Dye performance andamp; signal processing are species andamp; organ/cell type-specific. These systems have high degrees of cellular heterogeneity andamp; connective tissue relative to cultured cells. To develop a consistent system we will optimize our qOEP system specifically for work with electrically syncytial preparations of induced pluripotent stem cell derived (IPSCD) cardiac myocytes. The goal is to optimize a cell system (stem cell derived cardiac myocytes) andamp; the dyes to make an integrated optical system that makes qOEP available to almost any lab. This transformation will be similar to the way that the advent of molecular biology kits made complex molecular biological techniques accessible to all. The long term commercial opportunity is in cardiac safety screening to determine the arrhythmogenic potential of new drug candidates in stem cell derived cardiac myocytes. Our novel system has the potential to have significant impact in both the financial andamp; human health aspects of drug development. Successful completion of Phase I will result in a system consisting of sensors, dyes, illumination sources, andamp; software that can be used for beta testing in Phase II. In Phase II we will develop software, support, packaging andamp; optimized hardware for a turn-key commercial system.Optical imaging of electrical activity in cells enables the monitoring of cellular electrical activity to be observed without the use of cumbersome, difficult and potentially damaging mechanical electrodes. However, current optical methods are hampered by the unstable and damaging nature of currently available voltage sensitive dyes, and they do not give information on absolute membrane potential. This project will deliver a simple to use quantitative optical electrophysiology (qOEP) system, with long lasting dyes, a novel optical detector, and software to determine actual membrane potential (during an action potential and at rest) optimized for human induced pluripotent stem cell derived cardiac myocytes, which will result in affordable, stable, reproducible, reliable, high quality optical recordings suitable for identifying electrical activity in cardiac myocytes.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Cytocybernetics Inc SBIR Phase I Award, July 2020

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.